What Sufentanil Hameln Treats: Main Uses and Benefits

Sufentanil Hameln is commonly used in clinical settings that involve acute or unstable symptom patterns to help with symptomatic relief of severe, acute pain, such as the intense discomfort experienced immediately following major surgery or in critical care scenarios. This application is relevant in contexts marked by increased discomfort or tension, which may assist with maintaining functional stability.

It is applied across domains where additional symptomatic support is needed, primarily for symptomatic support during general anesthesia for surgical procedures and is relevant for easing symptoms related to physical discomfort in critically ill patients. The medication is considered relevant in contexts involving heightened systemic burden.

The medication is applied in addressing symptoms related to systemic imbalance and symptoms related to heightened physiological activity. It contributes to easing the overall symptom load.

Quick Fact: Relief for Symptoms related to Physical Discomfort

Absolute Contraindications

Sufentanil Hameln is contraindicated and must not be used in patients with a known hypersensitivity to sufentanil or other opioid agonists. The medicine is also strictly prohibited in patients with a known or suspected gastrointestinal obstruction, including paralytic ileus. Furthermore, the intravenous use of this medicine is contraindicated during labor prior to the umbilical cord being clamped.

---

Age and Physiological Restrictions

For age-related eligibility, the medicine is indicated for intravenous use in adults and pediatric patients aged one year and older. Safety and efficacy for epidural use in children under one year are not established. Use in geriatric patients (ge 65 years) requires close monitoring, and a dose reduction should be considered due to potential decreases in organ function.

Use is conditional in patients with impaired hepatic or renal function, requiring caution and close monitoring due to altered drug elimination. The medicine is not recommended during pregnancy or for lactating women. Use is also restricted for patients with acute conditions such as severe haemorrhage or shock (for epidural administration).

Interactions with other medicines and products

Concomitant use of Sufentanil Hameln with other medicines can lead to serious or life-threatening reactions. These interactions are primarily based on the drug's metabolism and its effects as a central nervous system (CNS) depressant.

High-Risk Combinations

Interacting Product Category	Potential Effect & Restriction
Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated. Use is forbidden concurrently or within 14 days of stopping MAOIs due to the risk of severe and unpredictable potentiation of opioid effects, including respiratory depression and Serotonin Syndrome.
CNS Depressants (e.g., Benzodiazepines, Alcohol, other Opioids, Sedatives)	Additive effects leading to profound sedation, respiratory depression, coma, and death. Concomitant use should be avoided or limited to the shortest possible duration with close monitoring.
CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)	Increased Sufentanil exposure due to reduced metabolism, raising the risk of prolonged or fatal respiratory depression. Patients require close monitoring; dose adjustments may be necessary.
Serotonergic Agents (various antidepressants)	Increased risk of Serotonin Syndrome, a potentially life-threatening condition involving changes in mental status, autonomic instability, and neuromuscular abnormalities.

Discontinuation of a CYP3A4 inducer (a medicine that increases the metabolism of sufentanil) may also result in a dangerous increase in sufentanil plasma concentration. Opioid antagonists, such as naltrexone, are contraindicated due to the risk of precipitating withdrawal.

How Sufentanil Hameln Works

Sufentanil functions as a full agonist primarily targeting the mu-opioid receptor (mu-OR), a type of G protein-coupled receptor (GPCR) predominantly located in the central nervous system (CNS), including the brain and spinal cord. Upon binding, Sufentanil induces a conformational change in the mu-OR, causing the intracellular Gi/Go protein complex to dissociate.

This dissociation initiates a signaling cascade that modulates neuronal activity. The free Galpha subunit inhibits the enzyme adenylyl cyclase, leading to a consequential decrease in the intracellular synthesis of cyclic adenosine monophosphate (cAMP). Simultaneously, the free Gbetagamma subunits facilitate the opening of G protein-coupled inwardly rectifying potassium channels ( GIRK), resulting in an efflux of potassium ions (K^+).

This K^+ efflux causes hyperpolarization of the neuronal membrane, which diminishes the neuron's excitability. Furthermore, the Gbetagamma subunits inhibit presynaptic voltage-gated calcium channels (Ca^2+), decreasing the influx of calcium ions. The net result is a reduction in the presynaptic release of excitatory neurotransmitters, effectively modulating nociceptive signal transmission within the CNS.

How to Use Sufentanil Hameln: Official Administration Guidelines

The use of Sufentanil Hameln is governed by strict regulatory protocols for administration in specialized settings. The medicine is supplied as a sterile solution and is exclusively administered via intravenous (IV) injection/infusion or epidural injection.

---

Official Dosing and Frequency

Dosing is highly individualized based on the patient's physical status and the intended medical procedure. For use as an adjunct to general anesthesia, the typical total initial IV dose ranges from 1 to 8 mcg/kg. When used as a primary anesthetic agent, initial IV doses of 8 mcg/kg or greater may be required.

The administration schedule is not fixed but is titrated (adjusted in real-time). Maintenance is achieved by administering 10 to 50 mcg incremental doses intravenously, given only as needed when signs indicate surgical stress or lessening of analgesia. The total dose administered must be adjusted to the remaining operative time anticipated to manage duration constraints.

---

Special Administration Constraints

The official administration protocol requires the solution to be administered only by specifically trained personnel within a medically supervised healthcare setting (such as a hospital). Prior to administration, the parenteral product must be visually inspected for any discoloration or particulate matter. Additionally, the drug must be delivered via slow injection or infusion. For pediatric patients aged 2 to 12 undergoing procedures like cardiovascular surgery, specific IV dose ranges (10 to 25 mcg/kg) are officially defined, and dosing in older adults requires individualization and caution.

Sufentanil is a synthetic opioid analgesic primarily used in medically supervised settings for its potent effects on pain perception and sedation. Recent clinical evidence, including randomized controlled trials and meta-analyses, focuses largely on its use in anesthesia and acute postoperative pain management.

Use in Anesthesia and Perioperative Care

Sufentanil, in its intravenous formulation, is frequently investigated as an analgesic adjunct in the maintenance of general anesthesia, especially during major surgical procedures. Studies often compare it with other potent opioids, such as fentanyl, in specialized contexts like cardiovascular or neurosurgical procedures.

Research has explored the compound's ability to maintain hemodynamic stability and provide favorable conditions for patients undergoing complex surgery. In some comparative studies, the onset of anesthesia and recovery time were reported to be similar when Sufentanil was used versus Fentanyl.

Postoperative and Acute Pain Management

The sublingual tablet system (SSTS) formulation of sufentanil has been a focus of trials for managing acute, severe pain in adults within certified medically supervised healthcare settings (e.g., hospitals and surgical centers). These studies aim to evaluate the efficacy of the non-invasive sublingual route compared to traditional intravenous patient-controlled analgesia (IV-PCA).

Randomized, controlled trials have found that the sublingual sufentanil tablet system reports differences in pain intensity reduction when compared to placebo in patients following procedures like abdominal or orthopedic surgery. Further research has investigated the impact of the sublingual administration route on patient satisfaction and the overall use of rescue analgesics in the post-anesthesia care unit (PACU).

Ongoing clinical investigations continue to assess the compound’s use in combination with other agents, as well as its comparative effectiveness in patients with specific medical needs, such as those with traumatic brain injury.

Common questions about Sufentanil Hameln (FAQ)

Q: How quickly is Sufentanil Hameln supposed to start working?

Official product information indicates that Sufentanil is characterized by a rapid onset of pain relief. Sufentanil’s characteristic of rapid onset of pain relief is one factor considered when it is used in supervised settings where quick pain suppression is needed. The specific amount of time it takes to start working can vary somewhat based on how the medicine is administered, such as by intravenous injection or sublingual tablet.

---

Q: How long does the effect of Sufentanil Hameln last in the body?

Following a single intravenous dose, the primary pain-relieving effect of Sufentanil is considered to be relatively short, lasting for approximately 30 to 60 minutes. However, official documents note that the medication's effect on breathing (respiratory depression) may persist longer than the period of pain relief. Official pharmacokinetic data shows the medication has an elimination half-life of around 162 minutes.

---

Q: What happens if Sufentanil Hameln is used at the same time as a muscle relaxant?

Sufentanil is frequently used as a pain-relieving supplement during general anesthesia, where it is often administered along with muscle relaxants. A potential issue noted in official use is that high doses of Sufentanil can cause muscle rigidity. If this occurs, it may interfere with the intended effect of the muscle relaxant. For this reason, official use requires professional oversight.

---

Q: Are there any food or drinks that interact with Sufentanil Hameln?

Regulatory warnings indicate that the use of Sufentanil with alcohol (a drink) is linked to a severe risk of additive effects, including profound central nervous system (CNS) depression, and is warned against in regulatory information. Furthermore, some official warnings advise against the consumption of grapefruit and grapefruit juice, as these may increase the blood levels and effects of Sufentanil.

---

Q: Is it true that Sufentanil Hameln is stronger than morphine?

Official information describes Sufentanil as a highly potent synthetic opioid. Clinical pharmacology reports estimate that Sufentanil is 500 to 1,000 times more potent than morphine and significantly more potent than the related opioid fentanyl.

---

Q: What is the difference between Sufentanil Hameln and remifentanil?

Both are powerful opioids, but official documents show they are handled differently by the body. Sufentanil has a longer context-sensitive half-life, which means its effects last longer after an infusion is stopped. Remifentanil, in contrast, has a shorter, more predictable action that allows for faster recovery when the medicine is discontinued.

---

Q: What are the signs of too much Sufentanil Hameln being given?

Signs of excessive opioid effect, including overdose, may involve a combination of symptoms such as profound sleepiness or coma, pupils that are smaller than normal (pinpoint pupils), and breathing that is significantly slowed or stopped (respiratory depression). Official safety documents emphasize that these symptoms are signs of a serious condition requiring immediate professional medical attention.

---

Q: Is there a reversal medicine available for Sufentanil Hameln effects?

Naloxone is an opioid antagonist medication approved by the FDA to rapidly reverse the dangerous effects of an opioid overdose, such as severe respiratory depression, including those caused by Sufentanil. Naloxone is available as an opioid antagonist.

---

Q: Are there different forms of Sufentanil Hameln available?

Yes. Sufentanil is available as an injectable solution (Sufentanil Citrate Injection) for intravenous or epidural use, which is typically administered in specialized settings. It is also available in some certified settings as a sublingual tablet system (DSUVIA) for acute pain management.

---

Q: Is Sufentanil Hameln commonly used in emergency medicine?

The sublingual tablet formulation (DSUVIA) is indicated for acute severe pain management in certified medically supervised healthcare settings, which may include emergency departments. Its use in other pre-hospital emergency settings is governed by specific regional protocols.

---

Q: Does Sufentanil Hameln contain penicillin or sulfa?

Official product descriptions state that the active ingredient in the medicine is Sufentanil citrate. The list of excipients (inactive ingredients) found in the injectable solution are generally standard compounds for parenteral products and do not include either penicillin or sulfa derivatives.

---

Q: Can Sufentanil Hameln make you feel confused?

Yes. Official regulatory documents indicate that while the most common central nervous system effects are sedation and dizziness, confusion is also listed as a potential side effect associated with this class of medication. Official information notes that patients with pre-existing impaired consciousness may have an increased risk.

---

Q: Does Sufentanil Hameln have a 'Black Box Warning' in the US?

Yes. The FDA-approved label for Sufentanil products in the US includes a Boxed Warning (also commonly referred to as a Black Box Warning). This warning highlights serious risks, including the potential for addiction, abuse, and misuse, and the danger of life-threatening respiratory depression and risks from concomitant use with CNS depressants.

---

Q: How is Sufentanil Hameln eliminated from the body?

Sufentanil is primarily eliminated from the body by metabolism in the liver, mainly involving the CYP3A4 enzyme system. Once processed, the resulting breakdown products (metabolites) are then mostly excreted from the body through the urine and, to a lesser extent, the feces.

---

Q: What is known about Sufentanil Hameln's effect on body temperature?

While it is not listed as a common or core side effect, clinical trial data submitted to regulatory authorities has listed increased body temperature (fever) as a potential adverse event.

---

Q: What is the difference between Sufentanil and Sufentanil Hameln?

Sufentanil is the generic name for the active drug substance that provides the medicinal effect. Sufentanil Hameln is the trade or brand name of a specific commercial product containing the drug substance, indicating that it is manufactured and marketed by the company Hameln.

How to Store and Dispose of Sufentanil Hameln?

Sufentanil Hameln solution must be stored at Controlled Room Temperature (20 C to 25 C), with excursions up to 30 C. The product must be protected from light and kept in its original container until use, following official regulatory requirements.

Child Safety and Disposal

As a potent Schedule II controlled substance, the medicine must be stored out of the sight and reach of children.

• Unused solution from a single-dose container must be discarded immediately after withdrawal.
• For disposal of unused product, utilize an authorized drug take-back program.
• If a take-back option is unavailable, the FDA recommends flushing the medicine down the toilet immediately to prevent accidental exposure, as it is on the list of high-risk opioids. Disposal must comply with local regulations.